FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced upcoming presentations at two major conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced upcoming presentations at two major conferences. The company will present at the 2024 ThinkEquity Conference in New York on October 30, 2024, at 10:30 a.m. ET, and at BIO-Europe 2024 in Stockholm on November 5, 2024, at 1:30 p.m. CET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. Their patent portfolio covers various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Details
News Market Reaction – FBLG
The recorded move for FBLG in the trading session of this news was -1.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.
2024 ThinkEquity Conference
Date: October 30, 2024
Location: New York, NY
Format: Company Presentation
Time: 10:30 a.m. ET
BIO-Europe 2024
Date: November 5, 2024
Location: Stockholm, Sweden
Format: Company Presentation
Time: 1:30 p.m. CET
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.